These studies have provided the basis for the development of humanized monoclonal antibodies that block PD-1 inhibitory signaling to enhance immune effector responses for the eradication of chronic infectious diseases with the potential for development of PD-1 agonists that can suppress the immune mediated pathology in autoimmune diseases. Here, PDCD1 is linked to autoimmune disease.